RYTM · Rhythm Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$115.02
+5.16 (+4.70%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.97B
Shares
69.33M
Volume · Nov 13
1.16M
Avg daily vol (3M)
997.95K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Rhythm Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Rhythm Pharmaceuticals, Inc. (RYTM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-11
Rhythm Pharmaceuticals, Inc. (RYTM) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-09
Rhythm Pharmaceuticals, Inc. (RYTM) November 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-03
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
Revenue
$92.13M
▲ 79.6% YoY Diluted EPS
$-0.61
Gross margin
86.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Rhythm Pharmaceuticals, Inc. (RYTM) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Rhythm Pharmaceuticals, Inc. (RYTM) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
Rhythm Pharmaceuticals, Inc. (RYTM) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript
Confident tone
International expansion
U.S. HO launch
CHI program and pipeline expansion
Revenue
$71.25M
▲ 46.9% YoY Diluted EPS
$-0.73
Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Rhythm Pharmaceuticals, Inc. (RYTM) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Rhythm Pharmaceuticals, Inc. (RYTM) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Rhythm Pharmaceuticals, Inc. (RYTM) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Confident tone
Acquired hypothalamic obesity (HO) launch
U.S. commercial execution and payer access
BBS base business performance
Revenue
$60.11M
▲ 83.8% YoY Diluted EPS
$-0.83
Gross margin
88.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-16
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Confident tone
FDA interactions and PDUFA
Bivamelagon (HO) phase 2 data and phase 3 planning
EMANATE trial program (genetic indications)
Revenue
$57.25M*
▲ 36.9% YoY Gross margin
91.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript
Confident tone
IMCIVREE commercial growth (BBS)
Acquired hypothalamic obesity (HO) launch
Prader-Willi syndrome (PWS) Phase II
Revenue
$51.30M
▲ 54.3% YoY Diluted EPS
$-0.82
Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript
Confident tone
BBS commercial growth (IMCIVREE)
Prader-Willi development
Acquired hypothalamic obesity (HO) regulatory progress
Revenue
$48.50M
▲ 66.8% YoY Diluted EPS
$-0.75
Gross margin
88.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Confident tone
BBS commercial performance (IMCIVREE)
Phase 3 HO trial and regulatory filing
Pipeline readouts (bivamelagon, PWS, RM-718)
Revenue
$32.70M
▲ 25.9% YoY Diluted EPS
$-0.81
Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript
Confident tone
Phase II Bivamelagon Trial Readout
Prader-Willi Syndrome Program
Bardet-Biedl Syndrome (BBS) Commercial Opportunity
Revenue
$41.83M*
▲ 72.6% YoY Gross margin
90.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript
Confident tone
IMCIVREE commercial execution and revenue growth
DAYBREAK trial results in genetic variants of obesity
International expansion and country launches
Revenue
$33.25M
▲ 47.8% YoY Diluted EPS
$-0.73
Gross margin
88.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript
Confident tone
BBS commercial execution
International expansion and pricing
Hypothalamic obesity Phase 3 trial
Revenue
$29.08M
▲ 51.3% YoY Diluted EPS
$-0.55
Gross margin
89.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2024 Earnings Call Transcript
Positive tone
BBS Commercial Execution
International Expansion
Next-Generation Pipeline
Revenue
$25.97M
▲ 126.4% YoY Diluted EPS
$-2.35
Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript
Confident tone
U.S. commercial performance and BBS launch
Hypothalamic obesity Phase 3 trial
International expansion (Europe)
Revenue
$24.23M*
▲ 175.7% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript
Revenue
$22.50M
▲ 425.3% YoY Diluted EPS
$-0.76
Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2023 Earnings Call Transcript
Revenue
$19.22M
▲ 112% YoY Diluted EPS
$-0.82
Gross margin
88.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2023 Earnings Call Transcript
Revenue
$11.47M
▲ 665.6% YoY Diluted EPS
$-0.92
Gross margin
87.6%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2022 Earnings Call Transcript
Revenue
$8.79M*
▲ 383.8% YoY Gross margin
88.3%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Call Transcript
Revenue
$4.28M
▲ 316.7% YoY Diluted EPS
$-0.79
Gross margin
88.4%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2022 Earnings Call Transcript
Revenue
$9.07M
▲ 3208.8% YoY Diluted EPS
$-0.89
Gross margin
95.8%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2022 Earnings Call Transcript
Revenue
$1.50M
▲ 4180% YoY Diluted EPS
$-1.05
▼ 216.7% YoY Gross margin
84.6%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2021 Earnings Call Transcript
Revenue
$1.82M*
Gross margin
87.0%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2021 Earnings Call Transcript
Revenue
$1.03M
Diluted EPS
$-0.70
Gross margin
78.4%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2021 Earnings Call Transcript
Revenue
$274,000
Diluted EPS
$-0.70
Gross margin
50.0%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Showing 1–30 of 30 webcasts
Key facts
CIK
1649904
CUSIP
76243J105
13F (30d)
263 filings
226 filers
Visit website
Investor relations